Novel Immune Checkpoint Inhibitors in Advanced Cervix Cancer

David M. O’Malley, MD, explores the use of PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of recurrent/metastatic cervical cancer.

EP. 1: Systemic Treatment of Metastatic/Recurrent Cervical Cancer

December 17th 2021

David M. O’Malley, MD, provides insight on the evolution of cervical cancer and reviews current systemic treatment options for recurrent and advanced disease.

EP. 2: Role of Anti–PD-1 and Anti-CTLA4 Agents in Cervical Cancer

December 17th 2021

An expert gynecologic oncologist discusses the rationale for using PD-L1 inhibitors and CTLA4 inhibitors in gynecologic cancers.

EP. 3: Recent Data on Use of Checkpoint Inhibitors for Cervical Cancer

December 17th 2021

Dr David M. O’Malley reviews ESMO 2021 updates evaluating the use of combination anti-PD-1 and anti-CTLA4 agents for recurrent and metastatic cervical cancer.

EP. 4: SITC 2021 Updates for Cervical Cancer: AGEN1181

December 17th 2021

David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.

EP. 5: Novel Agents for the Treatment of Cervical Cancer

December 17th 2021

Dr David M. O’Malley comments on emerging agents in the pipeline for the treatment of recurrent/metastatic cervical cancer and shares his approach to the sequencing of therapies.

EP. 6: Managing Adverse Events in Cervical Cancer Treatment

December 17th 2021

David M. O’Malley, MD, discusses the management of adverse events across various regimens for cervical cancer treatment and provides insight on future directions for disease management.